Literature DB >> 26770413

Identification of a novel molecular probe for recognition of human osteosarcoma cell using the cell-SELEX method.

Hua Wang1, Ji Liang2, Yan Ma1, Bo Sun1, Xianqian Li3, Yan Wei4, Guilian Fu5, Mingcheng Li5, Wei Xia5.   

Abstract

Osteosarcoma is the most common primary malignant bone tumor in adolescents and young adults. The lack of specific probes for human osteosarcoma hinders the early diagnosis and treatment of metastatic disease. In the present study, we have designed a novel aptamer using the cell-based Systematic Evolution of Ligands Exponential Enrichment (cell-SELEX) technique that specifically recognizes the U-2 OS human osteosarcoma cell line. Candidate aptamer families were identified through nine rounds of selection followed by sequence analysis and fluorescent labeling in addition to specific binding to U-2 OS cells. We identified one aptamer that showed high affinity and specificity to target cells, but did not recognize non-osteosarcoma negative control tumor cell lines. Moreover, we show that the selected aptamer can effectively be used as a molecular probe for specific recognition of clinical osteosarcoma samples. The generation of aptamer libraries can be used not only for the specific diagnosis of osteosarcoma, but also to build a platform for developing probe-carrier-antitumor drugs complexes and targeted therapies for osteosarcoma.

Entities:  

Keywords:  Cell-SELEX; aptamer; osteosarcoma U-2 OS

Year:  2015        PMID: 26770413      PMCID: PMC4694313     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  22 in total

Review 1.  [Cancer treatment by comprehensive regulation of anti-tumor immune network].

Authors:  Yutaka Kawakami
Journal:  Nihon Rinsho       Date:  2010-06

2.  Development of DNA aptamers using Cell-SELEX.

Authors:  Kwame Sefah; Dihua Shangguan; Xiangling Xiong; Meghan B O'Donoghue; Weihong Tan
Journal:  Nat Protoc       Date:  2010-06-03       Impact factor: 13.491

3.  Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation.

Authors:  Koji Itahana; Krishna P Bhat; Aiwen Jin; Yoko Itahana; David Hawke; Ryuji Kobayashi; Yanping Zhang
Journal:  Mol Cell       Date:  2003-11       Impact factor: 17.970

4.  Selection of aptamers for molecular recognition and characterization of cancer cells.

Authors:  Zhiwen Tang; Dihua Shangguan; Kemin Wang; Hui Shi; Kwame Sefah; Prabodhika Mallikratchy; Hui William Chen; Ying Li; Weihong Tan
Journal:  Anal Chem       Date:  2007-05-27       Impact factor: 6.986

Review 5.  Historical, current and future aspects of osteosarcoma treatment.

Authors:  S J Ham; H Schraffordt Koops; W T van der Graaf; J R van Horn; L Postma; H J Hoekstra
Journal:  Eur J Surg Oncol       Date:  1998-12       Impact factor: 4.424

6.  High affinity ligands from in vitro selection: complex targets.

Authors:  K N Morris; K B Jensen; C M Julin; M Weil; L Gold
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

7.  Role of the WWOX tumor suppressor gene in bone homeostasis and the pathogenesis of osteosarcoma.

Authors:  Sara Del Mare; Kyle C Kurek; Gary S Stein; Jane B Lian; Rami I Aqeilan
Journal:  Am J Cancer Res       Date:  2011-04-03       Impact factor: 6.166

8.  Postoperative infection and survival in osteosarcoma patients: Reconsideration of immunotherapy for osteosarcoma.

Authors:  Y U Chen; Song-Feng Xu; Ming Xu; Xiu-Chun Yu
Journal:  Mol Clin Oncol       Date:  2015-03-09

Review 9.  New molecular insights into osteosarcoma targeted therapy.

Authors:  Jilong Yang; Wei Zhang
Journal:  Curr Opin Oncol       Date:  2013-07       Impact factor: 3.645

10.  Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program.

Authors:  Lisa Mirabello; Rebecca J Troisi; Sharon A Savage
Journal:  Cancer       Date:  2009-04-01       Impact factor: 6.860

View more
  5 in total

Review 1.  Bone-Targeted Nanoparticle Drug Delivery System: An Emerging Strategy for Bone-Related Disease.

Authors:  Yulin Chen; Xianmin Wu; Jiadong Li; Yingying Jiang; Ke Xu; Jiacan Su
Journal:  Front Pharmacol       Date:  2022-05-31       Impact factor: 5.988

Review 2.  [Research advances in the role of aptamers in the diagnosis and targeted therapy of pediatric cancer].

Authors:  Yi-Bin Zhang; Yan-Peng Wang; Jing Liu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2018-05

3.  In vitro selection of DNA aptamers against human osteosarcoma.

Authors:  Khaliunsarnai Tsogtbaatar; Diana A Sousa; Debora Ferreira; Atakan Tevlek; Halil Murat Aydın; Eda Çelik; Ligia Rodrigues
Journal:  Invest New Drugs       Date:  2021-08-12       Impact factor: 3.850

Review 4.  Aptamers: novelty tools for cancer biology.

Authors:  Ricardo L Pereira; Isis C Nascimento; Ana P Santos; Isabella E Y Ogusuku; Claudiana Lameu; Günter Mayer; Henning Ulrich
Journal:  Oncotarget       Date:  2018-06-01

Review 5.  Generating Cell Targeting Aptamers for Nanotheranostics Using Cell-SELEX.

Authors:  Yifan Lyu; Guang Chen; Dihua Shangguan; Liqin Zhang; Shuo Wan; Yuan Wu; Hui Zhang; Lian Duan; Chao Liu; Mingxu You; Jie Wang; Weihong Tan
Journal:  Theranostics       Date:  2016-06-15       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.